Lineage Cell Therapeutics, Inc. LCTX

NYSE; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0000876343

A/B

on the A/B boundary of 367 graded peers in healthcare

rank 78 of 367; percentile 21.0; sampling error 2.5 points; lower is stronger


A B C D E

A/B, the bull




Scoreboard	
Profitability	A percentile 10.5
Solvency	C percentile 45.6
Growth and financing	C/D percentile 60.2
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $112.6M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: fortress balance sheet
Inputs computable	7 of 14
Graded from	filings received through Mar 5, 2026 255 days before the rescan; latest periodic filing 10-Q received Nov 12, 2026
Last close	$0.90 2026-11-13; market equity $227.7M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 5, 2026

- Collaborations," above. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator's resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator's evaluation of our technologies, product candidates, and market opportunities. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available for collaboration and could determine that such other collaboration is more attractive than a collaboration with us for our product candidate or technologies.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight


Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 10.5						
Gross profitability	not computable	32.3%				
latest aligned inputs end 2024-12-31; latest annual assets end 2025-12-31						
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing						
Accruals ratio	(39.5%)	(6.6%)		10.5	799	2025-12-31
Gross margin stability, five years	not computable	2.8 pts				
latest aligned inputs end 2024-12-31; latest annual assets end 2025-12-31						
Solvency, sleeve percentile 45.6						
Twelve-month failure probability	0.06%	0.08%		36.1	245	2026-09-30
Altman Z double-prime	(12.25)	(0.31)		65.8	743	2025-12-31
Net debt to EBITDA	not computable	1.82x				
one or more required annual facts are missing						
Interest coverage	not computable	(4.51x)				
one or more required annual facts are missing						
Current ratio	5.20x	2.96x		34.8	825	2025-12-31
Growth and financing, sleeve percentile 60.2						
Revenue growth, three-year compound	(0.3%)	10.1%		71.7	411	2025-12-31
Free cash flow growth, three-year compound	not computable	11.0%				
current FCF must be positive and base FCF must exceed $100,000						
Reinvestment rate	not computable	37.1%				
pretax income must exceed the validity floor and imply a 0%-100% tax rate						
Asset growth, three years	(3.1%)	2.3%		59.1	693	2025-12-31
Net share issuance, one year	9.1%	2.4%		49.7	627	2026-03-05

Among 367 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
73	Merit Medical Systems Inc. (MMSI)	19.7	A/B	
74	Boston Scientific Corp. (BSX)	19.9	A/B	
75	Zoetis Inc. (ZTS)	20.2	A/B	
76	Ocular Therapeutix, Inc. (OCUL)	20.5	A/B	dilution
77	Alpha PRO Tech Ltd. (APT)	20.8	A/B	
78	Lineage Cell Therapeutics, Inc. (LCTX)	21.0	A/B	
79	Siga Technologies Inc. (SIGA)	21.3	A/B	fortress balance sheet
80	West Pharmaceutical Services Inc. (WST)	21.6	A/B	fortress balance sheet
81	Axogen, Inc. (AXGN)	21.9	A/B	
82	Axsome Therapeutics, Inc. (AXSM)	22.1	A/B	
83	Rigel Pharmaceuticals Inc. (RIGL)	22.4	A/B	

What the price implies

at the 2026-11-13 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(50.2%)	(1.5%)	14
Distance from 52-week high	(53.3%)	(32.0%)	29
EBIT to enterprise value	not computable	(1.8%)	

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Free cash flow yield	(8.4%)	(1.0%)	36
Book value to price	0.29	0.29	50
Sales to price	0.06	0.29	20
Composite equity issuance, five years	44.8%	19.1%	65
Relative strength against the sector, log excess return	(0.87)	(0.18)	14

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$26.5M
Operating cash flow, four quarters	-$25.8M
Months of runway	12.3
Days since last periodic filing	3 (10-Q received Nov 12, 2026)
Median daily dollar volume, 63 sessions	$1.2M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$9.5M	2024-12-31	2026-03-05	10-K	26-093992
2	cost of revenue	us-gaap:CostOfRevenue	$334,000	2024-12-31	2025-03-10	10-K	25-036309
3	assets	us-gaap:Assets	$113.2M	2024-12-31	2026-03-05	10-K	26-093992
4	net income	us-gaap:NetIncomeLoss	-$63.5M	2025-12-31	2026-03-05	10-K	26-093992
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$18.9M	2025-12-31	2026-03-05	10-K	26-093992
6	assets	us-gaap:Assets	$112.6M	2025-12-31	2026-03-05	10-K	26-093992
7	gross profit	us-gaap:GrossProfit	$8.3M	2023-12-31	2024-03-07	10-K	24-027988
8	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$8.9M	2023-12-31	2025-03-10	10-K	25-036309
9	gross profit	us-gaap:GrossProfit	$14.0M	2022-12-31	2024-03-07	10-K	24-027988
10	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$14.7M	2022-12-31	2024-03-07	10-K	24-027988
11	gross profit	us-gaap:GrossProfit	$2.9M	2021-12-31	2023-03-09	10-K	23-007129
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$4.3M	2021-12-31	2023-03-09	10-K	23-007129
13	gross profit	us-gaap:GrossProfit	$1.4M	2020-12-31	2022-03-10	10-K	22-006520
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.8M	2020-12-31	2022-03-10	10-K	22-006520
15	current assets	us-gaap:AssetsCurrent	$59.2M	2025-12-31	2026-03-05	10-K	26-093992
16	current liabilities	us-gaap:LiabilitiesCurrent	$11.4M	2025-12-31	2026-03-05	10-K	26-093992
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$467.0M	2025-12-31	2026-03-05	10-K	26-093992
18	operating income	us-gaap:OperatingIncomeLoss	-$36.6M	2025-12-31	2026-03-05	10-K	26-093992
19	book equity	us-gaap:StockholdersEquity	$44.5M	2025-12-31	2026-03-05	10-K	26-093992
20	liabilities	us-gaap:Liabilities	$69.2M	2025-12-31	2026-03-05	10-K	26-093992
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$14.6M	2025-12-31	2026-03-05	10-K	26-093992
22	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$522,000	2025-12-31	2026-03-05	10-K	26-093992
23	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$23.1M	2024-12-31	2026-03-05	10-K	26-093992
24	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$565,000	2024-12-31	2026-03-05	10-K	26-093992
25	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$28.6M	2023-12-31	2025-03-10	10-K	25-036309

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

26	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$674,000	2023-12-31	2025-03-10	10-K	25-036309
27	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$1.1M	2022-12-31	2024-03-07	10-K	24-027988
28	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$413,000	2022-12-31	2024-03-07	10-K	24-027988
29	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$582,000	2022-12-31	2023-03-09	10-K	23-007129
30	operating income	us-gaap:OperatingIncomeLoss	-$22.5M	2022-12-31	2024-03-07	10-K	24-027988
31	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$25.8M	2022-12-31	2024-03-07	10-K	24-027988
32	income tax	us-gaap:IncomeTaxExpenseBenefit	$541,000	2022-12-31	2024-03-07	10-K	24-027988
33	current assets	us-gaap:AssetsCurrent	$60.0M	2022-12-31	2024-03-07	10-K	24-027988
34	current liabilities	us-gaap:LiabilitiesCurrent	$19.0M	2022-12-31	2024-03-07	10-K	24-027988
35	current assets	us-gaap:AssetsCurrent	$111.5M	2021-12-31	2023-03-09	10-K	23-007129
36	current liabilities	us-gaap:LiabilitiesCurrent	$47.1M	2021-12-31	2023-03-09	10-K	23-007129
37	assets	us-gaap:Assets	$101.0M	2023-12-31	2025-03-10	10-K	25-036309
38	assets	us-gaap:Assets	$123.7M	2022-12-31	2024-03-07	10-K	24-027988
39	shares outstanding	dei:EntityCommonStockSharesOutstanding	249,087,529	2026-03-05	2026-03-05	10-K	26-093992
40	shares outstanding	dei:EntityCommonStockSharesOutstanding	228,356,290	2025-03-04	2025-03-10	10-K	25-036309

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.